Symphogen:
Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers.
Founded in 2000 and headquartered in Denmark, Symphogen operates in the Biopharma, Biotechnology, Pharmaceutical industries. The company received a €67.50M Debt Financing investment on 22 October 2015 from Novo Holdings and PKA.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | €67.50M | 2 |
|
22 Oct 2015 |
| Private Equity Round | €41.00M | 3 |
|
03 May 2013 |
| Venture Round | €100.00M | 3 |
|
06 Jan 2011 |
| Venture Round | €33.00M | 1 | Essex Woodlands Healthcare Partners | 02 Feb 2009 |
| Private Equity Round | Unknown | 1 | GenenFUND | 10 Jun 2008 |
No recent news or press coverage available for Symphogen.
We care about your data, and we'd love to use cookies make your experience better.
